
ALT A bar chart showing the percent change in body weight from baseline to week 76, derived from an analysis-of-covariance model, for the treatment-regimen estimand, which incorporates the effects of any early discontinuation of survodutide or placebo, the use of protocol-prohibited obesity medications, and the effects of a prolonged dose-escalation period.

ALT This image presents two graphs showing the change from baseline in the estimated glomerular filtration rate. The top graph shows Mean Change from Baseline in eGFR over a period of months for groups taking finerenone and placebo. The bottom chart displays Mean eGFR Slopes for the total period, baseline to month 3, and month 3 to end of treatment for finerenone and placebo groups, highlighting treatment differences.



































